This page shows you the latest news items in this category. This is page number 9.
Total 2840 results found since Jan 2013.
New Issue of Johns Hopkins Nursing Magazine
.ReadMsgBody{
width:100%;
background-color:#ffffff;
}
.ExternalClass{
width:100%;
background-color:#ffffff;
}
.ExternalClass,.ExternalClass p,.ExternalClass span,.ExternalClass font,.ExternalClass td,.ExternalClass div{
line-height:100%;
}
html{
width:100%;
}
body{
-webkit-text-size-adjust:none;
-ms-text-size-adjust:none;
}
body{
margin:0;
padding:0;
}
table{
border-spacing:0;
}
img{
display:block !important;
}
table td{
border-collapse:collapse;
}
.yshortcuts a{
border-bottom:none !important;
}
a{
color:#005EB8;
text-decoration:n...
Source: Johns Hopkins University and Health Systems Archive - August 2, 2022 Category: Nursing Source Type: news
Opinion: The potential role of amyloid beta peptides as biomarkers of subconcussion and concussion - Boutte AM, Thangavelu B, Anagli J.
Concussion, often referred to as mild traumatic brain injury (mTBI), is a bump or blow to the head that causes damage to the brain. An invisible wound is often not observed (https://www.cdc.gov/headsup/basics/concussion_whatis.html) (1). Concussed patients...
Source: SafetyLit - August 1, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
UNISON-supported legal victory secures new holiday rights for all workers
All workers in the UK will now receive the same minimum level of paid annual holiday leave, regardless of how many hours they work, following a landmark legal judgment by the Supreme Court today (Wednesday).
The case, Harpur Trust v Brazel & UNISON, was taken by music teacher Lesley Brazel. She argued her employer was wrong to give her fewer days of annual leave than the legal minimum because she only worked during the school term.
UNISON got involved in the Brazel case because of its implications for thousands of school staff employed on term-time only contracts. The situation had previously been confused bec...
Source: UNISON Health care news - July 20, 2022 Category: UK Health Authors: Anthony Barnes Tags: News Press release annual leave term-time contracts Source Type: news
Picture of Auricular Tags
Title: Picture of Auricular TagsCategory: ImagesCreated: 1/5/2010 4:35:00 PMLast Editorial Review: 7/12/2022 12:00:00 AM
Source: MedicineNet Skin General - July 12, 2022 Category: Dermatology Source Type: news
What is Prolonged Grief Disorder?
Discussion
Grief is the process of experiencing different emotions, expressions and action in response to the death of someone the person cares about. This is a personal and private process. Grief can occur for other significant losses such as a divorce, job, or health. People may overlook loss of routine and special activities, presumed safety, and autonomy that can also cause loss and grief. Additional traumas of these loss types have been magnified especially in the past couple of years as the world lives with Covid. Mourning is a public process of showing grief. This often involves religious beliefs and customs, and cu...
Source: PediatricEducation.org - July 11, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 29, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells and CD3 o...
Source: Johnson and Johnson - June 29, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Receives Positive CHMP Opinion for IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, June 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA® (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity...
Source: Johnson and Johnson - June 24, 2022 Category: Pharmaceuticals Source Type: news
PCR home testing for people eligible for COVID-19 treatments, UKHSA (updated 22nd June 2022)
If you ' re eligible for a coronavirus (COVID-19) treatment, follow this guide on how to do a PCR test at home and register your test kit.
22 June 2022Updated ' PCR home test instructions... (print version) ' and accompanying HTML. Replaced ' COVID-19 Priority PCR test instructions (easy read) ' .
30 May 2022Updated 119 phone line opening hours.
Source: Current Awareness Service for Health (CASH) - June 22, 2022 Category: Consumer Health News Source Type: news
Products to Remove Moles, Skin Tags Can Be Harmful
Dermatologists and the FDA warn about dangers of using unregulated do-it-yourself products to remove moles, skin tags and another type of growth known as seborrheic keratoses.
Source: WebMD Health - June 20, 2022 Category: Consumer Health News Source Type: news
In Cambodia, researchers document the world's largest freshwater fish
Thanks to local fishers, a team of scientists on an expedition in Cambodia to tag Mekong River fish has discovered the largest freshwater fish ever documented--a 300-kilogram giant stingray that stretches nearly 4 meters from nose to tail.
"It's almost inconceivable that a fish this large still occurs in a river as heavily fished and developed as the Mekong," says Zeb Hogan, a fish biologist at the University of Nevada, Reno.
The team of scientists, part of an international collaboration called Wonders of the Mekong, tagged and released the record-breaking stingray (
Urogymnus polylepis
) thanks to having c...
Source: ScienceNOW - June 20, 2022 Category: Science Source Type: news
Two University of North Carolina School of Medicine Laboratories Develop Technique for Seeing How Proteins Change Shape In Vivo
UNC’s novel way to visualize the human proteome could lead to improved clinical laboratory tests along with the development of new therapies Diagnostic testing based on proteomics is considered to be a field with immense potential in diagnostics and therapeutics. News of a research breakthrough into how scientists can visualize protein activity within cells will […]
The post <strong>Two University of North Carolina School of Medicine Laboratories Develop Technique for Seeing How Proteins Change Shape In Vivo</strong> appeared first on Dark Daily.
Source: Dark Daily - June 17, 2022 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Laboratory Instruments & Laboratory Equipment Laboratory News Laboratory Pathology Laboratory Resources Laboratory Testing Precision Medicine anatomic pathology binder-tags biosensor cells clinical laboratory conformation Dark Dail Source Type: news
Society to Cells / Research News
.ReadMsgBody{
width:100%;
background-color:#ffffff;
}
.ExternalClass{
width:100%;
background-color:#ffffff;
}
.ExternalClass,.ExternalClass p,.ExternalClass span,.ExternalClass font,.ExternalClass td,.ExternalClass div{
line-height:100%;
}
html{
width:100%;
}
body{
-webkit-text-size-adjust:none;
-ms-text-size-adjust:none;
margin:0;
padding:0;
}
table{
border-spacing:0;
border-collapse:collapse;
}
img{
display:block !important;
}
table td{
border-collapse:collapse;
}
.yshortcuts a{
border-bottom:none !important;
}
a{
color:#E03C31;
...
Source: Johns Hopkins University and Health Systems Archive - June 15, 2022 Category: Nursing Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
